Adults 18 to 85, any sex, with Sarcopenia or Non Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Progression Free Survival (PFS)Primary· Follow-up were conducted every 2months during the first year and every 6 months for up to 5 years from enrollment. Progression-free survival was measured from the date of diagnosis until confirmed disease progression or death, whichever occurred first.
Due to the treatment frequency of lung cancer, we implemented the following follow-up schedule with actual follow-up completed for five years. Progression-free survival was measured from the date of diagnosis until the first occurrence of either: Objective tumor progression (confirmed by imaging per RECIST criteria), or death from any cause. whichever occurred first.
Group
Value
95% CI
Early-stage NSCLC With Sarcopenia
350
± 46.4
Early-stage NSCLC Without Sarcopenia
773
± 46.1
Overall Survival (OS)Secondary· Follow-up were conducted every 2months during the first year and every 6 months for up to 5 years from enrollment. overall survival was measured from the date of diagnosis until death or the final follow-up time.
Outcome of patient death from diagnosis to any cause or the final follow-up time
Group
Value
95% CI
Early-stage NSCLC With Sarcopenia
1319
± 172.5
Early-stage NSCLC Without Sarcopenia
402
± 49.9
Sponsor's own description
Growing evidence has confirmed that the prognosis of lung cancer is not only related to the stage of disease, but also to the physiological and psychological situation of the patients. Malignant tumors are often associated with weakness and cachexia, leading to less physical activities and worse moods. However, few studies that have attempted to investigate the impact of nutritional status on the prognosis of NSCLC. Existing applications of nutritional scoring systems in early-stage of NSCLC are very limited. Therefore, this study aims to observe the correlation between nutritional status and the prognosis of patients with early-stage NSCLC, to clarify the value in predicting the overall survival rate and progression-free survival rate of NSCLC patients, and to offer evidence for alleviating the social and economic burden of NSCLC.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT07500376 — Multimodal Nutritional and Sarcopenia Assessment for Risk Stratification in Lung Cancer Surgery
· recruiting
NCT07456956 — HIIT vs MCIT for Stroke-Related Sarcopenia in Ischemic Stroke
· NA
· recruiting
NCT07398495 — Multimodal Training Effects in Middle-Aged and Older Adults With Diabetic Sarcopenia
· NA
· recruiting
NCT07494916 — Effects of Functional Task Training on Muscle Health and Function in Older Adults With Sarcopenia
· NA
· active not recruiting
NCT07426159 — AI-Guided Sarcopenia Risk Assessment and Detection
· NA
· active not recruiting
Other Fudan University trials
Trials by the same sponsor.
NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer
· Phase 2
· not yet recruiting
NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer
· Phase 2
· not yet recruiting
NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre
· Phase 2
· not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer
· Phase 2
· not yet recruiting
NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer
· Phase 2
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fudan University
Last refreshed: 1 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05212285.